Business ❯ Mergers and Acquisitions

Pharmaceutical Industry

Drug Development Competition Investment Biotechnology Eli Lilly Regulatory Approval Cancer Treatment Cancer Treatments Biotech Companies Recent Acquisitions Orchard Therapeutics Acquisition Ophthalmology Genetic Research Genetic Testing Genomics Vaccine Development Obesity Drugs Startup Companies Perrigo Co Market Competition Rare Diseases Drugs Rare Disease Drugs AI in Drug Development

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal

The deal brings an oral obesity candidate into Pfizer’s pipeline, with YaoPharma finishing Phase 1 in Australia before a planned handoff.

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

BioNTech to Acquire CureVac for $1.25 Billion to Drive mRNA Cancer Therapy

Regeneron to Acquire 23andMe for $256 Million Following Bankruptcy Auction